Expanding Geographic Reach Krystal Biotech is actively expanding into European and Japanese markets with plans to launch its gene therapy product B-VEC in both regions in 2025. This provides opportunities to offer localized support, supply chain solutions, and regulatory consulting to facilitate smooth market entry.

Advanced Oncology Development The company's focus on developing innovative cancer therapies like KB707 and updating its strategic approach indicates ongoing commitments to oncology. This opens doors for collaborations in clinical trial services, laboratory instrumentation, and patient engagement solutions tailored to cancer research.

Investment & Funding Growth With significant funding of 160 million dollars and revenues between 50 to 100 million dollars, Krystal Biotech is well-positioned for further R&D investments and infrastructure expansion, potentially requiring advanced biotech equipment, software solutions, and strategic consulting services.

Technology and Data Management The company employs a tech stack including SAP, Fortinet, and Okta, indicating a focus on secure, integrated digital infrastructure. This presents opportunities for cybersecurity services, IT integrations, and enterprise software enhancements to support scalable research and commercialization efforts.

Strategic Industry Engagement Participation in major industry events like the TD Cowen Health Care Conference reflects Krystal Biotech’s active engagement in industry networks, creating opportunities for sponsorships, partnership development, and tailored communication solutions to strengthen market presence.